Wang, Yuxiang
Yang, Jie
Wild, Aaron T.
Wu, Wei H.
Shah, Rachna http://orcid.org/0000-0002-3639-7113
Danussi, Carla
Riggins, Gregory J.
Kannan, Kasthuri
Sulman, Erik P. http://orcid.org/0000-0003-4933-9120
Chan, Timothy A. http://orcid.org/0000-0002-9265-0283
Huse, Jason T.
Article History
Received: 6 June 2018
Accepted: 8 February 2019
First Online: 26 February 2019
Competing interests
: T.A.C. is a co-founder of Gritstone Oncology and holds equity. He holds equity in An2H. He acknowledges grant funding from Bristol-Myers Squibb, AstraZeneca, Illumina, Pfizer, An2H, and Eisai, and he has served as a paid advisor for Bristol-Myers Squibb, Illumina, Eisai, and An2H. M.S.K. has licensed the use of TMB for the identification of patients that benefit from immune checkpoint therapy to PGDx and T.A.C. receives royalties as part of this licensing agreement. The remaining authors declare no competing interests.